Zeinab Mohammadi1 
, Marie Saghaeian Jazi2 , Seyyed Mehdi Jafari1 , Seyed Mostafa Mir1 , Massoud Amanlou3 , Jahanbakhsh Asadi1
, Marie Saghaeian Jazi2 , Seyyed Mehdi Jafari1 , Seyed Mostafa Mir1 , Massoud Amanlou3 , Jahanbakhsh Asadi1
1- Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran ; Department of Clinical Biochemistry, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
2- Department of Clinical Biochemistry, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran ; Stem Cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran ,marie.saghaeian@goums.ac.ir
3- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
2- Department of Clinical Biochemistry, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran ; Stem Cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran ,
3- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Abstract: (378 Views)
Background: Bone remodeling involves a balance between osteoblast-driven formation and osteoclast-mediated resorption, with disruptions leading to diseases like osteoporosis. Midazolam (MDZ), known for its sedative properties, has shown effects on cellular differentiation and hydroxyapatite formation in dental cells. However, its role in promoting osteogenic differentiation in human bone marrow mesenchymal stem cells (hBMSCs) remains unexplored, motivating this study to investigate its potential in bone regenerative therapies.
Methods: We purchased hBMSCs from Royan Institute and cultured them in complete media with α-MEM, 10% FBS, and 1% pen/strep. Cell viability was determined with MTT assay in several concentrations of MDZ (0.125 to 1 µM) for 72 hours. Osteogenic differentiation was induced over 21 days using the selected doses of MDZ with osteogenic medium. The Alizarin Red S (ARS) staining was performed to determine the calcium deposit for osteoblast cells. Data were analyzed using repeated measure ANOVA, and a p-value <0.05 was considered statistically significant.
Results: The MTT results for several concentrations of MDZ (0.125 to 1 µM) showed no cytotoxic effects on hBMSCs after 72 hours. Furthermore, ARS staining revealed increased calcium deposits in 0.5 µM MDZ compared to untreated and DMSO groups (p =0.0001). These findings suggest that MDZ promotes mineralization at lower concentrations, highlighting its potential in osteogenic applications, while higher concentrations may lack differentiating effects.
Conclusion: Midazolam promotes osteogenic differentiation of hBMSCs, particularly at 0.5 µM concentration, without cytotoxic effects. These findings demonstrate that MDZ may be a potential compound for osteoblastogenesis; however, these findings require further in vivo studies to confirm the idea.
Methods: We purchased hBMSCs from Royan Institute and cultured them in complete media with α-MEM, 10% FBS, and 1% pen/strep. Cell viability was determined with MTT assay in several concentrations of MDZ (0.125 to 1 µM) for 72 hours. Osteogenic differentiation was induced over 21 days using the selected doses of MDZ with osteogenic medium. The Alizarin Red S (ARS) staining was performed to determine the calcium deposit for osteoblast cells. Data were analyzed using repeated measure ANOVA, and a p-value <0.05 was considered statistically significant.
Results: The MTT results for several concentrations of MDZ (0.125 to 1 µM) showed no cytotoxic effects on hBMSCs after 72 hours. Furthermore, ARS staining revealed increased calcium deposits in 0.5 µM MDZ compared to untreated and DMSO groups (p =0.0001). These findings suggest that MDZ promotes mineralization at lower concentrations, highlighting its potential in osteogenic applications, while higher concentrations may lack differentiating effects.
Conclusion: Midazolam promotes osteogenic differentiation of hBMSCs, particularly at 0.5 µM concentration, without cytotoxic effects. These findings demonstrate that MDZ may be a potential compound for osteoblastogenesis; however, these findings require further in vivo studies to confirm the idea.
Type of Article: Original article |
Subject:
Basic Medical Sciences
Received: 2024/12/12 | Accepted: 2025/04/9
Received: 2024/12/12 | Accepted: 2025/04/9
References
1. Song S, Guo Y, Yang Y, Fu D. Advances in pathogenesis and therapeutic strategies for osteoporosis. Pharmacol Ther. 2022:237:108168. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Pouresmaeili F, Kamalidehghan B, Kamarehei M, Goh YM. A comprehensive overview on osteoporosis and its risk factors. Ther Clin Risk Manag. 2018:14:2029-49. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289(5484):1504-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9(5):641-50. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Dominici M, Blanc KL, Mueller I, Slaper-Cortenbach I, Marini Fc, Krause Ds, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Lee DH, Kang SK, Lee RH, Ryu JM, Park HY, Choi HS, et al. Effects of peripheral benzodiazepine receptor ligands on proliferation and differentiation of human mesenchymal stem cells. J Cell Physiol. 2004;198(1):91-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008:(182):335-60. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Zhang T, Shao H, Xu K-q, Kuang L-t, Chen R-f, Xiu H-h. Midazolam suppresses osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. Eur Rev Med Pharmacol Sci. 2014;18(9):1411-8. [View at Publisher] [PMID] [Google Scholar]
9. So EC, Chen Y-C, Wang S-C, Wu C-C, Huang M-C, Lai M-S, et al. Midazolam regulated caspase pathway, endoplasmic reticulum stress, autophagy, and cell cycle to induce apoptosis in MA-10 mouse Leydig tumor cells. Onco Targets Ther. 2016:9:2519-33. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Ohno S, Kobayashi K, Uchida S, Amano O, Sakagami H, Nagasaka H. Cytotoxicity and type of cell death induced by midazolam in human oral normal and tumor cells. Anticancer Res. 2012;32(11):4737-47. [View at Publisher] [PMID] [Google Scholar]
11. Stevens MF, Werdehausen R, Gaza N, Hermanns H, Kremer D, Bauer I, et al. Midazolam activates the intrinsic pathway of apoptosis independent of benzodiazepine and death receptor signaling. Reg Anesth Pain Med. 2011;36(4):343-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
12. Mishra SK, Kang J-H, Lee CW, Oh SH, Ryu JS, Bae YS, et al., Midazolam induces cellular apoptosis in human cancer cells and inhibits tumor growth in xenograft mice. Mol Cells. 2013;36(3):219-26. [View at Publisher] [DOI] [PMID] [Google Scholar]
13. Karakida T, Onuma K, Saito MM, Yamamoto R, Chiba T, Chiba R, et al. Potential for drug repositioning of midazolam for dentin regeneration. Int J Mol Sci. 2019;20(3):670. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Baglio SR, Rooijers K, Koppers-Lalic D, Verweij FJ, Lanzón MP, Zini N, et al. Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species. Stem Cell Res Ther. 2015;6(1):127. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Pettersson LF, Kingham PJ, Wiberg M, Kelk P. In Vitro Osteogenic Differentiation of Human Mesenchymal Stem Cells from Jawbone Compared with Dental Tissue. Tissue Eng Regen Med. 2017;14(6):763-774. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Riss TL, Moravec RA, Niles AL, Duellman S, Benink HA, Worzella TJ, et al. Cell Viability Assays. Assay Guidance Manual. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2013. [View at Publisher] [Google Scholar]
17. Ghasemi M, Turnbull T, Sebastian S, Kempson I. The MTT Assay: Utility, Limitations, Pitfalls, and Interpretation in Bulk and Single-Cell Analysis. Int J Mol Sci. 2021;22(23):12827. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Hanna H, Mir LM, Andre FM. In vitro osteoblastic differentiation of mesenchymal stem cells generates cell layers with distinct properties. Stem Cell Res Ther. 2018;9(1):203. [View at Publisher] [DOI] [PMID] [Google Scholar]
19. Bernar A, Gebetsberger JV, Bauer M, Streif W, Schirmer M. Optimization of the Alizarin Red S Assay by Enhancing Mineralization of Osteoblasts. Int J Mol Sci. 2022;24(1):723. [View at Publisher] [DOI] [PMID] [Google Scholar]
20. Gregory CA, Gunn GW, Peister A, Prockop DJ. An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal Biochem. 2004;329(1):77-84. [View at Publisher] [DOI] [PMID] [Google Scholar]
21. PubChem Compound Summary for CID 4192. National Center for Biotechnology Information. 2025. [View at Publisher] [Google Scholar]
22. Reves JG. Midazolam: pharmacology and uses. Anesthesiology, 1985;62(3):310-24. [View at Publisher] [DOI] [Google Scholar]
23. Zhang T, Shao H, Xu K-q, Kuang L-t, Chen R-f, Xiu H-h. Midazolam suppresses osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. Eur Rev Med Pharmacol Sci. 2014;18(9):1411-8. [View at Publisher] [PMID] [Google Scholar]
24. Hidaka Y, Chiba-Ohkuma R, Karakida T, Onuma K, Yamamoto R, Fujii-Abe K, et al. Combined Effect of Midazolam and Bone Morphogenetic Protein-2 for Differentiation Induction from C2C12 Myoblast Cells to Osteoblasts. Pharmaceutics. 2020;12(3):218. [View at Publisher] [DOI] [PMID] [Google Scholar]
25. Harigaya H, Chiba-Ohkuma R, Karakida T, Yamamoto R, Fujii-Abe K, Kawahara H, et al. Potential for Drug Repositioning of Midazolam as an Inhibitor of Inflammatory Bone Resorption. Int J Mol Sci. 2024;25(14):7651. [View at Publisher] [DOI] [PMID] [Google Scholar]
26. Puchtler H, Meloan SN, Terry MS. On the history and mechanism of alizarin and alizarin red S stains for calcium. J Histochem Cytochem. 1969;17(2):110-24. [View at Publisher] [DOI] [PMID] [Google Scholar]
27. Karakida T, Onuma K, Saito MM, Yamamoto R, Chiba T, Chiba R, et al., Potential for Drug Repositioning of Midazolam for Dentin Regeneration. Int J Mol Sci. 2019;20(3):670. [View at Publisher] [DOI] [PMID] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |